The study evaluates the associations between major lipids and apolipoproteins and the risk of vascular disease. It analyzed data from 302,430 individuals without initial vascular disease across 68 long-term prospective studies, mostly in Europe and North America. Over 2.79 million person-years of follow-up, 8,857 nonfatal myocardial infarctions, 3,928 coronary heart disease deaths, 2,534 ischemic strokes, 513 hemorrhagic strokes, and 2,536 unclassified strokes were recorded. The study found that higher levels of non-HDL-C were strongly associated with increased risk of coronary heart disease (CHD), while higher HDL-C levels were associated with lower CHD risk. The hazard ratios (HRs) for CHD were 1.50 (95% CI, 1.39-1.61) for non-HDL-C and 0.78 (95% CI, 0.74-0.82) for HDL-C. For ischemic stroke, the HRs were 1.12 (95% CI, 1.04-1.20) for non-HDL-C. The study also found that the ratio of non-HDL-C to HDL-C and the ratio of apo B to apo AI were strongly associated with CHD risk. The HR for CHD was 1.50 (95% CI, 1.38-1.62) for the non-HDL-C/HDL-C ratio and 1.49 (95% CI, 1.39-1.60) for the apo B/apo AI ratio. The study concluded that lipid assessment in vascular disease can be simplified by measuring either total and HDL cholesterol levels or apolipoproteins without the need to fast and without regard to triglyceride. This conclusion is based on findings that HRs with non-HDL-C and HDL-C were nearly identical to those seen with apo B and apo AI. Additionally, HRs for vascular disease were at least as strong in participants who did not fast as in those who did. The study also found that triglyceride concentration was not independently related with CHD risk after controlling for HDL-C, non-HDL-C, and other standard risk factors. The study highlights the importance of measuring non-HDL-C and HDL-C in vascular risk assessment, as they are strongly associated with CHD risk in an approximately log-linear manner. The findings suggest that therapy directed at HDL-C as well as non-HDL-C may generate substantial additional benefit. The study also found that the association between triglyceride and CHD risk was not significant after adjusting for HDL-C and non-HDL-C. The study emphasizes theThe study evaluates the associations between major lipids and apolipoproteins and the risk of vascular disease. It analyzed data from 302,430 individuals without initial vascular disease across 68 long-term prospective studies, mostly in Europe and North America. Over 2.79 million person-years of follow-up, 8,857 nonfatal myocardial infarctions, 3,928 coronary heart disease deaths, 2,534 ischemic strokes, 513 hemorrhagic strokes, and 2,536 unclassified strokes were recorded. The study found that higher levels of non-HDL-C were strongly associated with increased risk of coronary heart disease (CHD), while higher HDL-C levels were associated with lower CHD risk. The hazard ratios (HRs) for CHD were 1.50 (95% CI, 1.39-1.61) for non-HDL-C and 0.78 (95% CI, 0.74-0.82) for HDL-C. For ischemic stroke, the HRs were 1.12 (95% CI, 1.04-1.20) for non-HDL-C. The study also found that the ratio of non-HDL-C to HDL-C and the ratio of apo B to apo AI were strongly associated with CHD risk. The HR for CHD was 1.50 (95% CI, 1.38-1.62) for the non-HDL-C/HDL-C ratio and 1.49 (95% CI, 1.39-1.60) for the apo B/apo AI ratio. The study concluded that lipid assessment in vascular disease can be simplified by measuring either total and HDL cholesterol levels or apolipoproteins without the need to fast and without regard to triglyceride. This conclusion is based on findings that HRs with non-HDL-C and HDL-C were nearly identical to those seen with apo B and apo AI. Additionally, HRs for vascular disease were at least as strong in participants who did not fast as in those who did. The study also found that triglyceride concentration was not independently related with CHD risk after controlling for HDL-C, non-HDL-C, and other standard risk factors. The study highlights the importance of measuring non-HDL-C and HDL-C in vascular risk assessment, as they are strongly associated with CHD risk in an approximately log-linear manner. The findings suggest that therapy directed at HDL-C as well as non-HDL-C may generate substantial additional benefit. The study also found that the association between triglyceride and CHD risk was not significant after adjusting for HDL-C and non-HDL-C. The study emphasizes the